CER Daily Newsfeed

Advancing Patient Registries and Expanding Real World Evidence Through Technology

(10/7, Ian Bonzani, Joydeep Sarkar, Clinical Trials Arena) comments “...Simplified data collection and deeper data sets inherently expand the insights that can be gathered from patient registries. Technology can play a crucial role in helping healthcare stakeholders make sense of this richer registry data and turn it into RWE that can enhance decision making across healthcare stakeholders. AI is becoming central to this shift. AI-powered data analysis, powered by large language models (LLMs), can evaluate the entire patient journey and treatment or clinical management of diseases for thousands of patients at once. By spotting associations in data that may be too intricate for even experienced professionals to see, AI can even enable shifts like the use of predictive interventions and support models.” Full

What Drives Beneficiaries To Switch Between MA And FFS Plans?

(10/7, William V. Padula, Health Affairs Forefront) comments “...MA plans may employ drug use management strategies such as prior authorization or step therapy. Prior authorization requires health care providers to obtain approval for certain medications and treatments, whereas step therapy requires patients to try and fail a lower-cost, insurer-preferred medication before progressing to a more costly alternative. These cost containment measures are often quite strict, which may limit access to high-cost and innovative therapies.” Full

Skin Substitutes: A Case For How ACOs Can Help Prevent Fraud, Waste, And Abuse

(10/7, Mara McDermott, Will Robinson, Kris Smith, Health Affairs Forefront) comments “...ACOs are well-equipped to adjust care delivery and networks to combat waste. Unlike unmanaged fee-for-service, ACOs constantly monitor claims feeds on their assigned patients to identify gaps in care and unusual spending patterns, and adjust resources to correct those gaps or patterns. For example, ACOs have deployed care management techniques, educated their patients and providers about the challenges of skin substitutes and their referral patterns, and established their own wound care services in certain cases to ensure high-quality care.” Full

‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE

(10/7, Eliza Slawther, Pink Sheet) reports “...European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.” Subscription Required

Video: Strategic Insights on Real-World Data in Japan: An Interview with Dr Keiko Asao

(10/7, The Evidence Base) “Japan has developed one of the most comprehensive real-world data (RWD) ecosystems in the world, supported by national databases, hospital networks, and pharmacy records. These resources are increasingly being used across the full spectrum of healthcare and life sciences – from R&D and pharmacovigilance to post-authorization safety studies, market access, and medical affairs. As policymakers and researchers seek to strengthen evidence generation, strategic approaches are vital to ensuring that RWD is applied effectively and responsibly. In this interview, Dr Keiko Asao (President, Kappa Medical K.K.) shares her perspectives on Japan’s evolving RWD strategy and its future potential.” View Video